Avantor, Inc.

NYSE:AVTR Lagerbericht

Marktkapitalisierung: US$5.2b

Avantor Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Avantor wird ein jährliches Gewinn- und Umsatzwachstum von 101.9% bzw. 2.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 70.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.4% betragen.

Wichtige Informationen

101.9%

Wachstumsrate der Gewinne

70.64%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum17.5%
Wachstumsrate der Einnahmen2.2%
Zukünftige Eigenkapitalrendite8.39%
Analystenabdeckung

Good

Zuletzt aktualisiert14 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • Nov 01

Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...

Recent updates

Narrativ-Update • May 01

AVTR: Reset Expectations And Execution Progress May Support Future Upside

Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.
Seeking Alpha • Apr 30

Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible

Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking Alpha
Narrativ-Update • Apr 16

AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing

Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.
Narrativ-Update • Apr 02

AVTR: Reset Expectations And Share Repurchases May Support Future Upside

The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.
Narrativ-Update • Mar 19

AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing

Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.
Narrativ-Update • Mar 05

AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential

Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.
Analyseartikel • Feb 13

The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%

Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...
Narrativ-Update • Feb 04

AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations

Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.
Narrativ-Update • Jan 21

AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility

Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.
Narrativ-Update • Jan 07

AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential

Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.
Narrativ-Update • Dec 14

AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves

Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.
Narrativ-Update • Nov 28

AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead

Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.
Narrativ-Update • Nov 14

AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025

Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.
Analyseartikel • Nov 01

Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...
Narrativ-Update • Oct 31

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.
Analyseartikel • Oct 28

There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise

Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...
Narrativ-Update • Oct 16

Pharma Contracts And R&D Will Drive Growth Amid Price Pressures

Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.
Analyseartikel • Sep 12

We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analyseartikel • Aug 12

Concerns Surrounding Avantor's (NYSE:AVTR) Performance

NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...
Analyseartikel • Jun 26

What Is Avantor, Inc.'s (NYSE:AVTR) Share Price Doing?

Avantor, Inc. ( NYSE:AVTR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...
Seeking Alpha • Apr 26

Avantor: A Healthier Diagnosis As Expectations Cool

Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

Avantor: Mundane Business, Solid Cash Flow, Potential New Risks

Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold?  An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Dec 18

Avantor: Durable FCF Generator Trading For Cheap

Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking Alpha
Seeking Alpha • Oct 24

Avantor: Uninspiring, Even Amidst Some Green Shoots

Summary Avantor shares have struggled on the back of a high valuation, significant debt, and lackluster growth, despite recent improvements in organic sales and a divestment. The company operates two segments: a $4.7 billion laboratory solutions business, and a $2.2 billion bioscience production business, with the latter having higher margins. Recent financials show declining sales and earnings, amidst high valuation and a demanding valuation. A $650 million divestment aims to reduce debt, but the overall risk-reward remains unattractive given the company's past performance and high leverage. Read the full article on Seeking Alpha
User avatar
Neues Narrativ • Aug 21

New Operating Model And Bioprocessing Innovations Promise Robust Growth And Market Leadership

Implementation of a new operating model and ongoing cost transformation initiatives are streamlining execution and improving net margins through cost savings.
Seeking Alpha • Aug 13

Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold

Summary AVTR stock is up 18% post Q2 FY'24 earnings, but momentum and quality continue to diverge. The company's balance sheet is saddled with debt, whilst earnings produced on capital are flattening. Valuations are unsupportive at >35x earnings, and I continue to rate AVTR a hold with little headroom for upside under present conditions. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NYSE:AVTR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20286,8623236497699
12/31/20276,63829163275315
12/31/20266,50123551564815
3/31/20266,552-551439573N/A
12/31/20256,552-530495624N/A
9/30/20256,575-82524644N/A
6/30/20256,666687556682N/A
3/31/20256,685716666809N/A
12/31/20246,784712692841N/A
9/30/20246,820310747919N/A
6/30/20246,826360736905N/A
3/31/20246,867260639792N/A
12/31/20236,967321724870N/A
9/30/20237,039364695824N/A
6/30/20237,176423721852N/A
3/31/20237,342610774911N/A
12/31/20227,512662710844N/A
9/30/20227,625598799939N/A
6/30/20227,603572809943N/A
3/31/20227,551534858979N/A
12/31/20217,386508843954N/A
9/30/20217,269466867959N/A
6/30/20217,040267904978N/A
3/31/20216,660169740804N/A
12/31/20206,39452868930N/A
9/30/20206,12771657711N/A
6/30/20206,026135576627N/A
3/31/20206,079-226480532N/A
12/31/20196,040-335N/A354N/A
9/30/20195,990-514N/A337N/A
6/30/20195,981-554N/A247N/A
3/31/20195,926-330N/A229N/A
12/31/20185,864-356N/A201N/A
9/30/20185,120-639N/A-16N/A
12/31/20171,247-415N/A-167N/A
12/31/2016691-42N/A73N/A
12/31/201563722N/A125N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AVTR wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).

Ertrag vs. Markt: AVTR wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: AVTR wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: AVTRDie Einnahmen des Unternehmens (2.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.6% pro Jahr).

Hohe Wachstumseinnahmen: AVTRDie Einnahmen des Unternehmens (2.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AVTRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.4%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/20 03:07
Aktienkurs zum Tagesende2026/05/20 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Avantor, Inc. wird von 29 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Michael RyskinBofA Global Research